Prostate stem cell antigen is overexpressed in prostate cancer metastases

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2591-2596

  Lam, John S ^a   Yamashiro, Joyce ^a   Shintaku, I Peter ^a   Vessella, Robert L ^b   Jenkins, Robert B ^c   Horvath, Steve ^a   Said, Jonathan W ^a   Reiter, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE STEM CELL ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VISCERAL METASTASIS;

BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 17644405097     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1842     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
3. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-48.
4. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40.
5. Antica M, Wu L, Scollay R. Stem cell antigen 2 expression in adult and developing mice. Immunol Lett 1997;55:47-51.
6. Classon BJ, Coverdale L. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc Natl Acad Sci U S A 1994;91:5296-300.
7. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
8. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
9. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001;61:4660-5.
10. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004;171:1117-21.
11. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-62.
12. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001;98:2658-63.
13. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000;60:5522-8.
14. Epstein JI, Algaba F, Allsbrook WC Jr, et al. Acinar adenocarcimona. In: World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Lyon (France): IARC Press; 2004. pp. 162-92.
15. Said JW, Pinkus JL, Shintaku IP, et al. Alterations in fascin-expressing germinal center dendritic cells in neoplastic follicles of B-cell lymphomas. Mod Pathol 1998;11:1-5.
16. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302.
17. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26:66-73.
18. Coulie PG, Van den Eynde BJ, van der Bruggen P, Van Pel A, Boon T. Antigens recognized by T-lymphocytes on human tumours. Biochem Soc Trans 1997;25:544-8.
19. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-7.
20. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2003.
21. Matsueda S, Yao A, Ishihara Y, et al. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24-prostate cancer patients. Prostate 2004;60:205-13.
22. Hara N, Kasahara T, Kawasaki T, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002;8:1794-9.
23. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003;195:356-72.